Spyre Therapeutics company information, Employees & Contact Information

Spyre Therapeutics Presents Promising Phase 1 Data for SPY072 at ACR Convergence Congress Quiver Quantitative

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025 PR Newswire

Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025 The Manila Times

42,500 Stock Options — Spyre Therapeutics Grants Options at $16.46 to Three Non‑Executive Employees Stock Titan

Intelligent Development Could Make Spyre Therapeutics Best In Show Seeking Alpha

Spyre Therapeutics Presents Promising Phase 1 Data for SPY002 at UEGW Congress Quiver Quantitative

6-Month Data: Spyre's SPY002 Shows Q3M Dosing Potential; Preclinical Combos Superior Stock Titan

Spyre Therapeutics Announces First Participant Dosed in Phase 1 Trial of SPY003, its Novel Half-life Extended IL-23 Antibody PR Newswire

Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025 The Manila Times

Spyre Therapeutics Announces Poster Presentation at the 20th Congress of the European Crohn's and Colitis Organisation PR Newswire

Introducing the IBM Spyre AI accelerator chip IBM Research

Spyre Therapeutics Announces Grants of Inducement Awards Yahoo Finance

Spyre Therapeutics to Unveil First Human Trial Data for Revolutionary IBD Antibody Treatment Stock Titan

Spyre Therapeutics Added to the Nasdaq Biotechnology Index PR Newswire

Spyre Therapeutics Phase 1 Trial Shows 3X Longer Half-Life in TL1A Antibody Programs | SYRE Stock News Stock Titan

Spyre Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update PR Newswire

Spyre Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update PR Newswire

Spyre Therapeutics Announces Expected Acceleration of SPY003 (IL-23p19) Clinical Timelines and Presentations at UEGW supporting Spyre's Portfolio of Potentially Best-in-Class Antibodies and Combinations PR Newswire

Aeglea BioTherapeutics Announces Name Change to Spyre Therapeutics, Appoints CEO and Additional Directors, and Expands Leadership Team to Develop Next-Generation Therapeutic Combinations for the Treatment of IBD PR Newswire

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer PR Newswire

Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trial of SPY001, its Novel Half-life Extended anti-α4β7 Antibody, for the Treatment of Inflammatory Bowel Disease PR Newswire

Spyre Therapeutics Closes $316.2 Million Public Offering of Common Stock Quiver Quantitative

Spyre Therapeutics Appoints Accomplished Biopharma and IBD Leader Mark C. McKenna, Former Chairman, President, and CEO of Prometheus Biosciences, to its Board of Directors PR Newswire

Spyre Therapeutics Doses First Patient in Pioneering Phase 2 SKYWAY Basket Trial of SPY072, the First Anti-TL1A Antibody Studied in Rheumatic Diseases Yahoo Finance

Spyre Therapeutics Announces Underwritten Public Offering of Common Stock and Pre-Funded Warrants Quiver Quantitative

IBM Introduces the Spyre Accelerator for Commercial Availability IBM Newsroom

Spyre (NASDAQ: SYRE) shows SPY072 Phase 1 PK for quarterly/twice‑yearly dosing at ACR Stock Titan

$275M Offering — Spyre Therapeutics Prices 14.86M Shares for IBD Biotech Stock Titan

Spyre Therapeutics to Offer Common Stock & Pre-Funded Warrants; 30-Day Underwriter Option Stock Titan

First-Ever Anti-TL1A Drug for 3M+ Rheumatic Patients: Spyre's SPY072 Enters Phase 2 Trial Stock Titan

SYRE - Spyre Therapeutics Latest Stock News & Market Updates Stock Titan

Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million MarketScreener

Spyre Therapeutics Appoints Dr. Sheldon Sloan as Chief Medical Officer Stock Titan

SYRE Stock Price and Chart — NASDAQ:SYRE TradingView

The Fantastic Four Just Added a New Member Screen Rant

TRP Spyre mechanical disc brake review BikeRadar